Beyond Permanent Genome Editing: Molecular Delivery Strategies for RNA Editing and Epigenome-Editing Therapeutics
International Journal of Molecular Sciences · 21.07.2026 · 27 (14) · 6467
DOI: 10.3390/ijms27146467 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.07.2026. Verfasst von Wajid Zaman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea. Hauptthemen laut MEDLINE: Epigenome Editing, RNA Editing, Gene Editing, Gene Transfer Techniques. Die Arbeit nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Reversible genetic medicines are emerging as controllable alternatives to permanent genome editing by enabling programmable modulation of RNA sequence, transcript abundance, chromatin state, and gene expression without irreversible genomic alteration. However, reversibility is not a single binary property: transient editor exposure, decay of the molecular effect, recovery of cellular function, and clinical capacity to stop, redose, or counteract treatment may diverge. This review therefore distinguishes mechanistic, functional, and clinical reversibility while examining targeted delivery systems for RNA-editing and epigenome-editing therapeutics. Key payloads include ADAR-recruiting oligonucleotides, CRISPR-Cas13 RNA editors, guide RNAs, chemically modified RNAs, editor-encoding mRNAs, dCas9 transcriptional regulators, DNA methylation editors, histone-modifying systems, and CRISPRoff-like platforms. We evaluate extracellular and intracellular delivery barriers, including nuclease degradation, immune recognition, renal clearance, liver uptake, cellular entry, endosomal escape, cytoplasmic release, nuclear localization, chromatin access, editing-window duration, off-target activity, immunogenicity, repeat-dosing feasibility, manufacturing, quality control, potency assays, and regulatory translation. Overall, delivery systems for reversible genetic medicines should be judged by tissue selectivity, functional editing, duration of action, reversibility after treatment withdrawal, safety, manufacturability, and clinical controllability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea.
- Faculty of Sports Science, Ningbo University, Ningbo 315211, China.
ORCID-Profile: Wajid Zaman, Asma Ayaz
Zitieren
APA
Zaman, W., & Ayaz, A. (2026). Beyond Permanent Genome Editing: Molecular Delivery Strategies for RNA Editing and Epigenome-Editing Therapeutics. International Journal of Molecular Sciences, 27(14), 6467. https://doi.org/10.3390/ijms27146467
Vancouver
Zaman W, Ayaz A. Beyond Permanent Genome Editing: Molecular Delivery Strategies for RNA Editing and Epigenome-Editing Therapeutics. International Journal of Molecular Sciences. 2026;27(14):6467. doi:10.3390/ijms27146467
BibTeX
@article{Zaman2026,
author = {Zaman, Wajid and Ayaz, Asma},
title = {Beyond Permanent Genome Editing: Molecular Delivery Strategies for RNA Editing and Epigenome-Editing Therapeutics},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6467},
doi = {10.3390/ijms27146467}
}
EUVIMED